The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations

The present retrospective study was conducted to evaluate the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring driver mutations. Patients with NSCLC harboring driver mutations who received ICIs (nivolumab or pembrolizumab) were re...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Mol Clin Oncol
Main Authors: Sakamoto, Hiroaki, Tanaka, Hisashi, Shiratori, Toshihiro, Baba, Keisuke, Ishioka, Yoshiko, Itoga, Masamichi, Taima, Kageaki, Hasegawa, Yukihiro, Takanashi, Shingo, Tasaka, Sadatomo
פורמט: Artigo
שפה:Inglês
יצא לאור: D.A. Spandidos 2019
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482391/
https://ncbi.nlm.nih.gov/pubmed/31031976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1838
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים